NEW YORK (GenomeWeb News) - Transgenomic said yesterday that it has struck agreements with two undisclosed pharmaceutical companies to provide genetic mutation discovery services for two Phase II clinical trials.

The company said the deals will be worth a total of $500,000 in the first half of 2008, but it did not disclose the names of the companies involved or provide further financial details.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.